Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19

  1. Julie Boucau
  2. Rockib Uddin
  3. Caitlin Marino
  4. James Regan
  5. James P. Flynn
  6. Manish C. Choudhary
  7. Geoffrey Chen
  8. Ashley M. Stuckwisch
  9. Josh Mathews
  10. May Y. Liew
  11. Arshdeep Singh
  12. Zahra Reynolds
  13. Surabhi L. Iyer
  14. Grace C. Chamberlin
  15. Tammy D. Vyas
  16. Jatin M. Vyas
  17. Sarah E. Turbett
  18. Jonathan Z. Li
  19. Jacob E. Lemieux
  20. Amy K. Barczak
  21. Mark J. Siedner
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

We enrolled seven individuals with recurrent symptoms following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log 10 copies/mL) were detected at enrollment and for a median of 17 days after initial diagnosis. Three of seven had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

Related articles

Related articles are currently not available for this article.